| Market Cap | 13.30M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.46M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -17.00% |
| Sales | 1.87M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -21.00% |
| Dividend | N/A | Price/Book | 0.55 | EPS next 5Y | - | 52W High Chg | -55.00% |
| Recommedations | - | Quick Ratio | 3.37 | Shares Outstanding | 199.62M | 52W Low Chg | 50.00% |
| Insider Own | 15.05% | ROA | -14.40% | Shares Float | 117.39M | Beta | 0.52 |
| Inst Own | 16.53% | ROE | -26.40% | Shares Shorted/Prior | -/- | Price | 0.05 |
| Gross Margin | 80.09% | Profit Margin | -238.69% | Avg. Volume | 2,466 | Target Price | - |
| Oper. Margin | -47.43% | Earnings Date | May 28 | Volume | 10,120 | Change | 0.00% |
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.